What does the recent ALT analyst rating from William Blair mean?

A maintained Market Perform means William Blair views ALT as neutral. It is not a buy or sell signal and suggests monitoring clinical and financial catalysts rather than taking large new positions.

Did William Blair set an ALT price target with this rating?

No. The March 05, 2026 note reiterated Market Perform without publishing an ALT price target, so investors lack firm upside/downside quantification from this firm.

How should investors react to the ALT analyst rating?

Investors should treat the maintained rating as a hold signal, watch upcoming clinical readouts and cash guidance, and consider position size relative to risk tolerance and Meyka AI’s B grade assessment.

Where can I read the analyst note and the company earnings transcript?

William Blair’s note was published on StreetInsider and Altimmune’s Q4 2025 transcript is on Seeking Alpha; see the Sources section below for links to both.

Analyst Ratings

William Blair Maintains Market Perform on ALT (Altimmune, Inc.) March 2026

ByDanny Kontos March 6, 2026

William Blair maintained a Market Perform rating on Altimmune, Inc. (ALT) on March 05, 2026, signaling a neutral stance toward the stock. The firm left its view unchanged in a note published at 11:31 AM ET, with no price target disclosed and no upgrade or downgrade. This reiteration comes as Altimmune reports Q4 2025 results and investor attention turns to clinical progress and cash runway. The ALT analyst rating holds implications for investors weighing risk versus reward in a biotech mid-cap with a market cap of $309,341,837.